Cargando…

Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens

Detalles Bibliográficos
Autores principales:	Marcelin, AG, Charpentier, C, Ferreira, C, Wirden, M, Lemarchand, C, Descamps, D, Calvez, V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112912/ http://dx.doi.org/10.1186/1758-2652-13-S4-P136

Ejemplares similares

Darunavir resistance spectrum in darunavir-na#239;ve patients harboring virological failure to antiretroviral therapy
por: Marcelin, AG, et al.
Publicado: (2010)

Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment
por: Marcelin, Anne-Genevieve, et al.
Publicado: (2014)

Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens
por: Ross, Lisa L, et al.
Publicado: (2015)

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
por: Kumar, P, et al.
Publicado: (2010)

Pharmacokinetics and 48-week Safety and Antiviral Activity of Fosamprenavir-containing Regimens in HIV-infected 2- to 18-year-old Children
por: Fortuny, Claudia, et al.
Publicado: (2014)

Changes in lipid profiles after switching to a protease inhibitor-containing cART - unfavourable effect of fosamprenavir in obese patients
por: Gyalrong-Steur, M, et al.
Publicado: (2011)

Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population
por: Rusconi, Stefano, et al.
Publicado: (2012)

Week 48 efficacy of 900/100 mg daily of darunavir/ritonavir in treatment-experienced HIV-1 patients with virological success: DARDAR study
por: Schneider, L, et al.
Publicado: (2010)

Prevalence of drug resistance mutations in HIV-1 protease gene from North India
por: Azam, Mohd, et al.
Publicado: (2012)

Pharmacokinetics, Safety and Antiviral Activity of Fosamprenavir/Ritonavir-containing Regimens in HIV-infected Children Aged 4 Weeks to 2 Years—48-week Study Data
por: Cotton, Mark, et al.
Publicado: (2014)

Post-licensing safety of fosamprenavir in HIV-infected children in Europe†
por: Judd, Ali, et al.
Publicado: (2014)

Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice
por: Llibre, JM, et al.
Publicado: (2010)

Description of the L76V Resistance Protease Mutation in HIV-1 B and “Non-B” Subtypes
por: Charpentier, Charlotte, et al.
Publicado: (2013)

Tolerance and durability of abacavir/lamivudine (ABC/3TC)-containing regimens: results from a large prospective French cohort
por: Cuzin, L, et al.
Publicado: (2010)

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors
por: Malet, Isabelle, et al.
Publicado: (2017)

Relating protease inhibitor resistance at time of virological failure with drug exposure
por: Van Luin, M, et al.
Publicado: (2010)

Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients
por: Flamholc, Leo, et al.
Publicado: (2008)

Antiretroviral regimen complexity as a predictor of adherence
por: Boyle, C, et al.
Publicado: (2010)

Prevalence and specificity of autoantibodies to defensins in sera of patients with systemic autoimmune diseases
por: Terzoglou, AG, et al.
Publicado: (2005)

A systematic review of published antimalarial clinical trials: parasite clearance of artemisinin-containing regimens in the treatment of uncomplicated malaria
por: Das, Debashish, et al.
Publicado: (2012)

Efficacy of once daily darunavir/ritonavir 800/100 mg in PI/r-experienced HIV-1 infected patients with suppressed HIV-1 replication: the RADAR study
por: Ghosn, J, et al.
Publicado: (2010)

Minority M184V variants in women exposed to 3TC/FTC-containing lopinavir-ritonavir (LPVr) regimens in pregnancy
por: Surah, S, et al.
Publicado: (2010)

HIV drug resistance in children with treatment failure to first-line regimens in Ho Chi Minh City, Vietnam
por: Nhung, VTT, et al.
Publicado: (2010)

Prevalence, incidence and risk factors for acute renal failure in the intensive care unit
por: Rabbat, C, et al.
Publicado: (2005)

Potential immune of recombinant serine protease of Corynebacterium pseudotuberculosis
por: Almeida, Daniela Droppa, et al.
Publicado: (2014)

PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine
por: Munseri, P, et al.
Publicado: (2012)

A novel HIV vaccine targets the 12 protease cleavage sites
por: Luo, M, et al.
Publicado: (2012)

Efficient immune reconstitution in HIV+ naïve patients (pts) starting a first lopinavir/ritonavir-containing regimen with low CD4 counts
por: Merlini, E, et al.
Publicado: (2010)

Developing juvenile localized scleroderma (jLS) consensus treatment regimens for comparative effectiveness studies
por: Li, Suzanne C, et al.
Publicado: (2012)

HIV drug resistance profile of HIV-1 CRF 01_AE protease and integrase coding regions in HIV infected Cambodian patients failing LPV-based 2(nd) line antiretroviral regimen
por: Nouhin, Janin, et al.
Publicado: (2011)

G140S mutation rescues HIV-1 IN integration defect due to Q148H in vitro and in vivo
por: Delelis, Olivier, et al.
Publicado: (2009)

Naturally occurring protease inhibitor resistance mutations and their frequencies in HIV proviral sequences of drug-naïve sex workers in Nairobi, Kenya
por: Sampathkumar, Raghavan, et al.
Publicado: (2014)

The use of a darunavir/ritonavir once-daily regimen in two pregnant women
por: Lambert, JS, et al.
Publicado: (2010)

INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels
por: Lambert-Niclot, Sidonie, et al.
Publicado: (2019)

Block & replacement regimen is more cost effective than titration regimen in treating thyrotoxicosis in children, without more harm
por: Kwok, MK Anne, et al.
Publicado: (2015)

Prevalence and risk factors for chronic obstructive lung disease in HIV-infected patients in the HAART era
por: Madeddu, G, et al.
Publicado: (2010)

Comparative efficacy and safety of regimens including ritonavir-boosted lopinavir or nevirapine in antiretroviral-naïve HIV-1-infected individuals
por: Pereira, A, et al.
Publicado: (2010)

Predictive factors of noninvasive ventilation failure in a pediatric ICU
por: Alith, Marcela B, et al.
Publicado: (2015)

Decrease in the 30-day heart failure (HF) Rehospitalization Rate after the implementation of a HF managed protocol
por: Correa, AG, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_3k4d1d63ukqp50luf5al5fl5s1